GlassScriptPhysician profile
Cynthia Nix
NPI 1891904868
$4,560.70
in general payments reported to CMS, 2019-2025
17 companies · $950 in 2025
The $950 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.56 · 2020: $252 · 2021: $240 · 2022: $598 · 2023: $1,271 · 2024: $1,170 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,390.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,280.16 | 2022-2025 | Cequa |
| Alcon Vision LLC | $743.40 | 2019-2025 | Lensx, Clareon, Tryptyr |
| Glaukos Corporation | $512.92 | 2020-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Tarsus Pharmaceuticals, INC. | $403.51 | 2024-2025 | Xdemvy |
| Allergan, INC. | $321.92 | 2019-2021 | |
| Abbvie INC. | $302.19 | 2022-2025 | |
| Biotissue Holdings INC. | $256.39 | 2024-2025 | |
| Dompe US, INC. | $206.16 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $170.66 | 2023-2025 | Miebo, Vyzulta, Scoutpro Osmolarity System |
| Tearlab Corp | $118.15 | 2023 | Tearlab Osmolarity System |
| Rxsight INC | $79.55 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $58.05 | 2020-2023 | Tecnis Iol |
| Thea Pharma INC. | $32.67 | 2023 | Iyuzeh |
| Amgen INC. | $21.47 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.80 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $16.85 | 2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $15.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Nix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.